Lab Rats series: Activating ‘natural killers’ for cancer with Zumutor
Zumutor Biologics is betting on a novel cancer drug that activates natural killer cells. With its lead candidate in phase 1 trials, the startup faces the challenge of turning early clinical signals into a licensing deal and investor returns.
Mint asks for a subscription to read the full story. If you have one, sign in on their site.
0 comments